Please use this identifier to cite or link to this item: https://doi.org/10.1007/s10637-007-9085-0
DC FieldValue
dc.titleA multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
dc.contributor.authorMa, B.
dc.contributor.authorLam, K.C.
dc.contributor.authorMo, F.
dc.contributor.authorChan, A.T.C.
dc.contributor.authorZee, B.
dc.contributor.authorMok, T.
dc.contributor.authorGoh, B.C.
dc.contributor.authorSoo, R.
dc.contributor.authorWang, L.Z.
dc.contributor.authorTan, E.H.
dc.contributor.authorLeong, S.S.
dc.date.accessioned2011-09-29T05:53:49Z
dc.date.available2011-09-29T05:53:49Z
dc.date.issued2008
dc.identifier.citationMa, B., Lam, K.C., Mo, F., Chan, A.T.C., Zee, B., Mok, T., Goh, B.C., Soo, R., Wang, L.Z., Tan, E.H., Leong, S.S. (2008). A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Investigational New Drugs 26 (2) : 169-173. ScholarBank@NUS Repository. https://doi.org/10.1007/s10637-007-9085-0
dc.identifier.issn01676997
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/27208
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1007/s10637-007-9085-0
dc.sourceScopus
dc.subject3-AP
dc.subjectGemcitabine
dc.subjectMethemoglobinemia
dc.subjectNon-small-cell lung cancer
dc.subjectTriapine
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1007/s10637-007-9085-0
dc.description.sourcetitleInvestigational New Drugs
dc.description.volume26
dc.description.issue2
dc.description.page169-173
dc.identifier.isiut000253765400007
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.